Pancreatic Cancer Research

ResearcherKurume UniversityActive in the last 2 years

Toru Nakamura

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-3999-9627; OpenAlex author ID A5101813952. Sources: OpenAlex.

Their work

Papers
31 (first author 11, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
60
Papers, trials and grants by year

2013: 1 paper · 2014: none · 2015: 3 papers · 2016: 2 papers · 2017: 2 papers · 2018: 3 papers · 2019: 6 papers · 2020: 4 papers · 2021: 1 paper · 2022: 3 papers · 2023: 2 papers · 2024: 2 papers · 2025: 2 papers

Papers 31

  1. Normal tissue complication probability model for severe radiation-induced lymphopenia in patients with pancreatic cancer treated with concurrent chemoradiother… Co-author DOI 10.1016/j.phro.2024.100690↗
  2. Survival after neoadjuvant and induction FOLFIRINOX versus gemcitabine-nab-paclitaxel in patients with resected localised pancreatic adenocarcinoma: an interna… Co-author DOI 10.1038/s41416-025-03025-1↗
  3. Therapeutic activity of retroviral replicating vector-mediated gene therapy in combination with anti-PD-1 antibody in a murine pancreatic cancer model. First author DOI 10.1038/s41417-024-00810-7↗
  4. Concurrent targeting of GSK3 and MEK as a therapeutic strategy to treat pancreatic ductal adenocarcinoma. Co-author DOI 10.1111/cas.16100↗
  5. Drosophila Screening Identifies Dual Inhibition of MEK and AURKB as an Effective Therapy for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/0008-5472.can-22-3762↗
  6. Tumor Growth Suppression of Pancreatic Cancer Orthotopic Xenograft Model by CEA-Targeting CAR-T Cells. Co-author DOI 10.3390/cancers15030601↗
  7. Predictors of Long-Term Survival in Pancreatic Ductal Adenocarcinoma after Pancreatectomy: TP53 and SMAD4 Mutation Scoring in Combination with CA19-9. Co-author DOI 10.1245/s10434-022-11630-0↗
  8. ASO Author Reflections: Constructed Scoring System Using TP53 and SMAD4 Mutations Combined with Carbohydrate Antigen 19-9 in Pancreatic Ductal Adenocarcinoma. First author DOI 10.1245/s10434-022-11735-6↗
  9. Tumor-Informed Approach Improved ctDNA Detection Rate in Resected Pancreatic Cancer. First author DOI 10.3390/ijms231911521↗
  10. A novel laparoscopic near-infrared fluorescence spectrum system for photodynamic diagnosis of peritoneal dissemination in pancreatic cancer. Co-author DOI 10.1016/j.pdpdt.2020.102157↗
  11. Signaling adaptor protein Crk is involved in malignant feature of pancreatic cancer associated with phosphorylation of c-Met. Co-author DOI 10.1016/j.bbrc.2020.01.105↗
  12. Immunological Gene Signature Associated With the Tumor Microenvironment of Pancreatic Cancer After Neoadjuvant Chemotherapy. Co-author DOI 10.1097/mpa.0000000000001665↗
  13. Role of Dimerized C16orf74 in Aggressive Pancreatic Cancer: A Novel Therapeutic Target. First author DOI 10.1158/1535-7163.mct-19-0491↗
  14. Clinical Outcomes of Biliary Drainage during a Neoadjuvant Therapy for Pancreatic Cancer: Metal versus Plastic Stents. First author DOI 10.5009/gnl18573↗
  15. Clinical usefulness of conversion surgery for unresectable pancreatic cancer diagnosed on multidetector computed tomography imaging: Results from a multicenter… First author DOI 10.1002/ags3.12272↗
  16. Glycosylation of ascites-derived exosomal CD133: a potential prognostic biomarker in patients with advanced pancreatic cancer. Co-author DOI 10.1007/s00795-019-00218-5↗
  17. A Preoperative Prognostic Scoring System to Predict Prognosis for Resectable Pancreatic Cancer: Who Will Benefit from Upfront Surgery? Co-author DOI 10.1007/s11605-018-3972-x↗
  18. Phase 2 Study of Neoadjuvant Treatment of Sequential S-1-Based Concurrent Chemoradiation Therapy Followed by Systemic Chemotherapy with Gemcitabine for Borderl… First author DOI 10.1016/j.ijrobp.2019.07.004↗
  19. Prognostic relevance of tertiary lymphoid organs following neoadjuvant chemoradiotherapy in pancreatic ductal adenocarcinoma. Co-author DOI 10.1111/cas.14023↗
  20. [Ⅲ.Management of Biliary Drainage in Patients Undergoing Neo-Adjuvant Therapy for Biliary or Pancreatic Cancer]. First author PMID 31631131↗
  21. Survival benefit of conversion surgery for patients with initially unresectable pancreatic cancer who responded favorably to nonsurgical treatment. Co-author DOI 10.1002/jhbp.565↗
  22. Therapeutic activity of retroviral replicating vector-mediated prodrug activator gene therapy for pancreatic cancer. Co-author DOI 10.1038/s41417-018-0020-7↗
  23. Oncological emergency surgery for metachronous large and small bowel metastases after pancreaticoduodenectomy for pancreatic cancer: a case report. Co-author DOI 10.1186/s40792-018-0506-4↗
  24. The impact of margin status determined by the one-millimeter rule on tumor recurrence and survival following pancreaticoduodenectomy for pancreatic ductal aden… First author DOI 10.1007/s00595-016-1420-7↗
  25. Molecular targeting of cell-permeable peptide inhibits pancreatic ductal adenocarcinoma cell proliferation. First author DOI 10.18632/oncotarget.21939↗
  26. Stromal Palladin Expression Is an Independent Prognostic Factor in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1371/journal.pone.0152523↗
  27. Clinical impact of chemotherapy to improve tumor microenvironment of pancreatic cancer. Co-author DOI 10.4251/wjgo.v8.i11.786↗
  28. Concomitant major vessel resection in pancreatic adenocarcinoma. Co-author DOI 10.1080/00325481.2015.1032180↗
  29. Chemotherapy-Derived Inflammatory Responses Accelerate the Formation of Immunosuppressive Myeloid Cells in the Tissue Microenvironment of Human Pancreatic Canc… Co-author DOI 10.1158/0008-5472.can-14-2921↗
  30. Inhibition of Eph receptor A4 by 2,5-dimethylpyrrolyl benzoic acid suppresses human pancreatic cancer growing orthotopically in nude mice. First author DOI 10.18632/oncotarget.5729↗
  31. Novel aspects of preoperative chemoradiation therapy improving anti-tumor immunity in pancreatic cancer. Co-author DOI 10.1111/cas.12119↗

Closest collaborators

The 25 strongest of 60 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Satoshi Hirano · 28 shared papers, 2013–2024 · strength 2.68
  2. Takahiro Tsuchikawa · 20 shared papers, 2013–2024 · strength 1.63
  3. Toshiaki Shichinohe · 17 shared papers, 2013–2024 · strength 1.33
  4. Yoshitsugu Nakanishi · 10 shared papers, 2017–2022 · strength 0.87
  5. Toshimichi Asano · 10 shared papers, 2017–2022 · strength 0.87
  6. Kazuho Inoko · 6 shared papers, 2015–2024 · strength 0.47
  7. Masato Ono · 4 shared papers, 2017–2022 · strength 0.46
  8. Yasutoshi Kimura · 4 shared papers, 2019–2022 · strength 0.38
  9. Masayo Motoya · 4 shared papers, 2019–2022 · strength 0.38
  10. Takako Ooshio · 2 shared papers, 2023–2024 · strength 0.34
  11. Sho Sekiya · 2 shared papers, 2023–2024 · strength 0.34
  12. Junki Fukuda · 2 shared papers, 2023–2024 · strength 0.34
  13. Ryodai Yamamura · 2 shared papers, 2023–2024 · strength 0.34
  14. Masahiro Sonoshita · 2 shared papers, 2023–2024 · strength 0.34
  15. Yusuke Mizukami · 2 shared papers, 2022 · strength 0.34
  16. Shintaro Takeuchi · 5 shared papers, 2015–2018 · strength 0.28
  17. Osamu Sato · 3 shared papers, 2017–2023 · strength 0.27
  18. Norio Katoh · 2 shared papers, 2019–2025 · strength 0.27
  19. Tsuyoshi Hayashi · 3 shared papers, 2019–2020 · strength 0.26
  20. Toshihiro Kushibiki · 4 shared papers, 2015–2020 · strength 0.25
  21. Shota Kuwabara · 3 shared papers, 2017–2022 · strength 0.24
  22. Hironobu Takano · 4 shared papers, 2015–2018 · strength 0.20
  23. Shinya Tanaka · 2 shared papers, 2020 · strength 0.19
  24. Yusuke Uchinami · 1 shared paper, 2025 · strength 0.19
  25. Fuki Koizumi · 1 shared paper, 2025 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.